PD1 inhibitor induced inverse lichenoid eruption: a case series.
Publication/Presentation Date
12-15-2020
Abstract
The increased use of monoclonal antibodies that target the immune checkpoint T cell receptor programmed death-1 (PD1) to treat numerous solid tumors has led to several reports describing associated cutaneous adverse events. Although lichenoid reactions have been well described, we propose that PD1 inhibitor-induced inverse lichenoid eruption (PILE) is a distinct variant. We describe two patients who presented with nearly identical deeply erythematous, malodorous, eroded anogenital plaques with focal crusting. Diagnosis of PILE was established given the biopsy findings and temporal association with PD1 inhibitor therapy. Treatment with clobetasol ointment was successful without necessitating discontinuation of immunotherapy. The findings were consistent with the only other previously published case of inverse lichenoid eruption in the groin secondary to PD1 inhibitors.
Volume
26
Issue
12
ISSN
1087-2108
Published In/Presented At
Sethi, M., Garg, V., Lee, J. B., & Yang, S. (2020). PD1 inhibitor induced inverse lichenoid eruption: a case series. Dermatology online journal, 26(12), 13030/qt66b8298z.
PubMedID
33423421
Department(s)
Department of Pathology and Laboratory Medicine
Document Type
Article